Ascletis Pharma Inc (2VJ)

This is the biggest thing since the Advent acquisition, if not bigger.

Never thought about that. That would certainly save them a few hundred million. Is there enough capacity, compression or whatever the criteria is to piggyback on Williams? Would they prefer to have their own control with a new station?

..dude......will get 'em both, and the G-wagon is ordered, and the 4-runner......not firm on the wrangler, but definitely a wrangler............gotta fill up the garages with a new fleet.........boys toys................($40mios in the tip jar??)...............

.....the POS.....???.

Robert Half receives three Canadian HR Reporter Readers' Choice Awards 2026, for 11th consecutive yearJuly 3, 2026 12:38 PM
PR Newswire (Canada) class="legendSpanClass"TORONTO, class="legendSpanClass"July 3, 2026 /CNW/ - Global talent so

$OSRH to new long investors buy 10k shares and HOLD and while turning your 10k shares to 60k shares 👇 

•  Details: One non-transferable CVR per share held as of the record date (targeted for July 31, 2026). Subject to legal counsel approval.

•  Tiered Rewards: T

Slide16 “Overall Conclusions: The survival benefit associated with DCVax-L treatment reflects a true treatment affect and was underestimated in the original analysis”

https://nwbio.com/wp-content/uploads/NWBT-BNOS-slides-7-3-26MB-LP-final.pdf

i will wait for Monday to grab some more ??

Brazen22, you’re trying to reduce three years of regulatory progress to one sentence: “You don’t have an approved MAA.”

Of course we don’t — yet. Approval is the destination. We have a validated MAA. What matters is whether NWBO has completed the steps that regulators require before a

THATS WHEN i ACCUMULATE. At The hammerbottom.

Nonbelievers . . . . . C L E A R The R U N W A Y
$3.50 CDN is pretty strong support.

https://investorshub.advfn.com/uimage/uploads/2026/7/3/vwgethg_july_3_2y_plunge_sell.jpg

Slides! JAMA study UNDERESTIMATED survival benefit

https://nwbio.com/wp-content/uploads/NWBT-BNOS-slides-7-3-26MB-LP-final.pdf

I agree with your thinking and also what needs to be considered is after decimating the board, just a desire to be acquired doesn’t automatically make that happen.  Some other party has to be interested in acquiring Amarin. What happens then if no one steps up?

This is another post built on false equivalence. Sharing Y-90 doesn't make two products the same any more than sharing aspirin makes every painkiller identical.

You keep calling them competitors while ignoring they're fundamentally different technologies. One is a hydrogel platform, t

Im glad I held my shares past $0.15

And don’t forget your buddy, AF. … .. . 

HappyLibrarian,

You are mistakenly overstating my claim which is a common problem so no harm no foul. Manufacturing transition preparedness is what I am suggesting must be in place. Artisan will be utilized to start as NWBO has consistently stated and the MIA is based on that model.

Just knowing JCTB1 is here is good enuf for me, okay.
See ya all topside….
$LBRG

Have at it Brazen! ;)  … .. . :) 

Every biotech founder believes their design choice was the right one — that’s true of BetaGlue’s surgeon-founder and it was true of Fisher/Korenko too. Design rationale explains intent, not outcome. The question that matters is what the trial data shows for each product, not why either team picked t

Digital USIO & AI Payment Potential:

(USIO In-Part):

"Embedded payments are the hidden engine under the hood of the apps and platforms we use every day. When you buy a ticket through a sports app or pay for a round of golf lessons online, embedded payments are doing the

$Ownership😘 of @ this point w/ irrefutable DD
🤔https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177573771&txt2find=reactor

https://x.com/thommic/status/2072760144774005081

Just so you know the clock on the 12 month restricted period for SNTX divvy shares began on June 17th, 2026. It doesn't matter that the deliverance of shares to the gtvh shareholders is taking some time. The clock begins when SNTX creates and issues the shares...meaning the day OTCmarkets shows the

I like this line in couple of PSM analysis slides:

“ Conclusion: Based on these more precisely matched comparisons,
the survival benefit with DCVax-L was likely underestimated
in the original analysis”

Very encouraging . Now let’s see when MHRA does its jo